(redirected from Tazocin)
Also found in: Thesaurus, Medical.
Related to Tazocin: Tazobactam


A semisynthetic broad-spectrum penicillin, C23H27N5O7S, used in its sodium form often in combination with the beta-lactamase inhibitor tazobactam, and active against a variety of gram-positive and gram-negative bacteria.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.piperacillin - a synthetic type of penicillin antibiotic (trade name Pipracil) used for moderate to severe infections
penicillin - any of various antibiotics obtained from Penicillium molds (or produced synthetically) and used in the treatment of various infections and diseases
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
References in periodicals archive ?
Most of the multidrug resistant isolates were sensitive to Polymyxins B, Tazocin and Fusidic acid (Fig.
The ecology of antibiotic use in the ICU: homogeneous prescribing of cefepime but not tazocin selects for antibiotic resistant infection.
Eighteen (72%) patients were treated with ciprofloxacin (Cipro 400 mg flakon, Biopharma, Istanbul, Turkey), two (8%) patients with ciprofloxacin (Cipro 400 mg flakon, Biopharma, Istanbul, Turkey) and piperacillin tazobactam (Tazocin 4.5 g flakon, Pfizer, New York, USA), two (8%) patients with meropenem (Meronem 1 g flakon, Astra Zeneca, Cambridge, England), two (8%) patients with ciprofloxacin (Cipro 400 mg flakon, Biopharma, Istanbul, Turkey) and daptomycin (Cubicin 500 mg flakon, Novartis, Basel, Switzerland), and one (4%) patient with meropenem (Meronem 1 g flakon, Astra Zeneca, Cambridge, England) and linezolid (Zyvoxid 600 mg flakon, Pfizer, New York, USA).
Multi drug resistance pattern of Klebsiella pneumoniae (n=9) showed 9 (100%) resistance to Ampicillin, 7 (77.8%) to Ciprofloxacin, 6 (66.7%) to Cotrimoxazole, Clavulanic acid-Amoxicillin, Gentamycin and Tigecycline, 5 (55.6%) to Ceftriaxone and Sulbactam-piperacillin (Combicin), 4 (44.4%) to Tazobactum-piperacillin (Tazocin), 3 (33.3%) Amikacin, Imepenim and Doxycycline.
The cause of her symptoms was not identified and the patient was treated prophylactically for Sepsis of Unknown Origin (SUO) with IV tazocin for five days.
Afterwards, patient clinically improved and was resumed on intravenous vancomycin and Tazocin. Ten days later, patient was discharged home on Rifampicin and Ciprofloxacin for a total of 12-week course.
Tazobactam with piperacillin (Tazocin) was administered as per local guidelines.
67y old 14 days Pneumonia, then Ribs 7,8,9 male ventilator dependence left (fully treated with Tazocin before surgery).
The ciprofloxacine treatment was changed after 16 days to intravenous vancomycin 2x1 g (Edicin, Lek farmacevtska druzba d.d.; Ljubljana, Slovenia) and piperacillin/tazobactam 3x4.5 g (Tazocin, Wyeth Lederle S.p.A.; Catania, Italy) daily, according to the recommendation of the clinical pharmacologist.
The lowest rates of resistance were detected for: tazocin (6.25%), amikacin (12.5%) and gentamicin (14.84%).